Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung CancerMi Ran Yun, Byoung Chul Cho, Han Na Kang et al.|Clinical Cancer Research|2020Cited by 116
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancerMi Ran Yun, Byoung Chul Cho|EMBO Molecular Medicine|2019Cited by 60
Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLCSeung Yeon Oh, Mi Ran Yun|Clinical Cancer Research|2022Cited by 47
The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLCSeung Yeon Oh, Mi Ran Yun|Cell Reports Medicine|2025Cited by 5